INNV · InnovAge Holding Corp.

The thesis

InnovAge's fiscal 2027 guide of $105–115 million adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) is intact, but the controlling private-equity funds sold 10 million shares at $9.25 on 22 September 2026 and the shares closed at $9.12 on 27 October 2026, still below that price. The shares are more likely to lag the S&P 500 than lead it over the next three months. The first-quarter fiscal 2027 report on 3 November 2026 and any further fund sales settle it.

The company confirmed on 20 October 2026 that it will report results for the quarter ended 30 September 2026 after the market close on Tuesday 3 November 2026, with a conference call at 5 p.m. Eastern. It is the first test of the guide issued on 8 September 2026: revenue of $1,050–1,085 million, adjusted EBITDA of $105–115 million and ending census of about 8,625–8,850 participants. Fiscal 2026 revenue was $989.7 million and adjusted EBITDA $94.6 million (company release, 8 September 2026).

The share price has moved sideways since the prior note. The adjusted close was $9.08 on 14 October 2026 and is $9.12 on 27 October 2026, which is 24.7% below the 52-week high of $12.11. The three-month price change is -21.4%. The 14-day relative strength index (RSI) is 49.7, down from 60.5 on 14 October 2026 and up from 20.8 on 1 October 2026, so the oversold reading of early October has fully unwound.

The narrative is maturing: the turnaround is well known, and attention since the 22 September 2026 offering has centred on the owners' selling rather than on earnings. The 3 November 2026 report is the first item that can change that.

Bullish and bearish views on InnovAge Holding Corp.

The bull case on InnovAge Holding Corp. (INNV), in brief: Guidance sits above reported results. The bear case: The controlling holders sold into strength.

Bull case

• Guidance sits above reported results. The 8 September 2026 release guided fiscal 2027 adjusted EBITDA to $105–115 million, against $94.6 million reported for fiscal 2026. The low end of the range is above the year just completed.
• The company took no part in the sale. InnovAge sold no shares and received no proceeds from the 10 million-share offering (pricing release, 23 September 2026). The share count and balance sheet were not changed by the deal.
• The report date is now fixed. The company's 20 October 2026 announcement sets results for 3 November 2026, which puts the guide under test within a week of this note.
• One target remains far above the price. KeyBanc raised its target to $14 from $13 on 9 September 2026 and kept Overweight (Investing.com). MarketBeat listed a consensus target of $10.50 on 10 October 2026.

Bear case

• The controlling holders sold into strength. The offering priced days after the shares closed at $10.92 on 18 September 2026, and after-hours trading fell 9.43% to $9.65 on the announcement (Investing.com and Benzinga, 22 September 2026). The sellers know the business better than any outside investor.
• Neither the registration nor the prospectus discloses a lock-up on the remaining shares.
• An executive also sold after the offering. MarketBeat reported on 10 October 2026 that insider Nicole Damato sold 23,814 shares at $8.70 on 25 September 2026.
• Analyst sentiment is cautious. MarketBeat's tally on 10 October 2026 showed one Buy, one Hold and two Sell ratings, a consensus rating of Reduce, and a 50-day moving average of $10.34 that sits well above the $9.12 close.
• Reported profit is still negative. The fiscal 2026 net loss attributable to InnovAge was $2.5 million against $94.6 million of adjusted EBITDA (company release, 8 September 2026).

Price setup

The last adjusted close is $9.12 (27 October 2026). The 52-week high is $12.11. The 1 October 2026 close of $8.80 is the recent low, and the 22 September 2026 offering price of $9.25 sits just above the current close.

MarketBeat put the 50-day moving average at $10.34 on 10 October 2026, so the shares trade well under their recent average. The RSI(14) of 49.7 is neutral.

Crowding evidence points the other way from a squeeze. Insider and fund selling came into strength in September, and the earnings date is six sessions away. Coverage is only a few analysts wide, so one firm's revision moves the published average target.

Catalysts, next 30 days

• Any date: a Form 4 or Schedule 13D amendment from the selling funds would state the remaining stake and show whether more sales follow.

Elapsed catalysts

• ~22 October 2026 (elapsed): the underwriters' 30-day option on up to 1,500,000 more shares at $9.25 ran out. No filing in the recent record shows an exercise, and the option was out of the money while the shares traded below $9.25. (passed 15d ago)
• 3 November 2026, after the close: first-quarter fiscal 2027 results, with a call at 5 p.m. Eastern. This is the first test of the $105–115 million adjusted EBITDA guide and of census growth toward 8,625–8,850. (passed 3d ago)

What would change the view

The case for lagging performance breaks if the 3 November 2026 report shows adjusted EBITDA running at or above the pace needed for $105–115 million, census growth toward the guided range, and a raised or reaffirmed guide with the shares holding above the $9.25 offering price. The case also weakens if the selling funds state a stake that rules out further near-term sales.

The opposite outcome ends the thesis outright: a withdrawn or lowered fiscal 2027 guide, a new CMS enrollment freeze at a center, or another sell-down priced below $9.25. A daily close below $8.00, under the 1 October 2026 close of $8.80, would also end it.

What it trades with

InnovAge trades with managed-care and senior-health names when medical-cost trends move the group. Its revenue comes from capitated Medicare and Medicaid payments for the frail elderly, so state rate changes and CMS oversight matter more than consumer demand. Medical-cost guidance cuts from UnitedHealth, Humana, Centene or Elevance with InnovAge falling on unchanged estimates would point to sector pressure. The controlling-holder overhang is specific to the company and has moved the shares independently of the sector since 22 September 2026.